Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

BACKGROUND: The functional activity of the organic cation transporter 1 (OCT-1) protein (OCT-1 activity) is an excellent predictor of molecular response and progression-free survival in patients with newly diagnosed chronic phase chronic myeloid leukemia treated with imatinib as front-line therapy....

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: White, Deborah L., Radich, Jerald, Soverini, Simona, Saunders, Verity A, Frede, Amity K., Dang, Phuong, Cilloni, Daniela, Lin, Peter, Mongay, Lidia, Woodman, Richard, Manley, Paul, Slader, Cassandra, Kim, Dong Wook, Pane, Fabrizio, Martinelli, Giovanni, Saglio, Giuseppe, Hughes, Timothy P.
التنسيق: Artigo
اللغة:Inglês
منشور في: Ferrata Storti Foundation 2012
الموضوعات:
Original Articles and Brief Reports
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3366658/
https://ncbi.nlm.nih.gov/pubmed/22207690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.056457
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة